Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q3 2020 · 10-Q
Revenue$6.55M$6.55M+87.3% vs Q3 2019 Net Income-$8.86M-$8.86MN/M vs Q3 2019 EPS Diluted-$0.25-$0.25N/M vs Q3 2019 Operating Income-$9,699,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$11,947,000N/M Margins · derivedOperating margin-148.0%+107.8 pt vs Q3 2019
Net margin-135.1%+118.3 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end